RECRUITING

Impact of OnabotulinumtoxinA (BOTOX®) on Stress

Talk to us

Conditions

Stress (Psychology)StressHealthy Adult Female ParticipantsStress, PsychologicStress, Psychological CumulativeStress, PhysiologicalStress ResponseStress LevelsStress PerceptionBOTOXPSSPerceived stress scaleinjectionreductionBTAfacial rejuvenationaesthetic procedurepsychological impactclinical trialfacial expressionsstress reliefstress reductionchemodenervation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this prospective single-center, blinded\*, randomized, proof-of-concept study is to determine whether OnabotulinumtoxinA (BOTOX®) injections will change the level of stress perceived by generally healthy adult female participants. It is hypothesized that BOTOX® injections will be associated with decreases in perceived stress levels, measured by scores on the Perceived Stress Scale (PSS) questionnaire. The primary outcome measure is a chronological decrease in PSS scores between any two points of the study period. Comparison of the placebo- and BOTOX®-treated participant scores will either support or disprove the study hypothesis. Qualified participants who meet the study requirements, including a one-time completion of basic laboratory testing before treatment. The treatment visit starts on day-1 of a 12-week period, which consists a total of four clinic visits and one online visit, which involve: * vital signs and Body Mass Index (BMI) measurements * basic/interval history and physical * 2 Perceived Stress Scale (PSS) questionnaires * injection of 64 units of either BOTOX® or sterile salt solution * stay for 60-minutes after treatment for monitoring and to complete study tasks

Official Title

Pilot Study to Identify the Impact of OnabotulinumtoxinA (BOTOX®) on Patient Perceived Stress.

Quick Facts

Study Start:2025-01-20
Study Completion:2025-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06778421

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Subjects capable of giving informed consent in the English language
  2. 2. Females 18-65 years of age
  3. 3. Perceived Stress Scale (PSS) ≥ 14 at screening.
  4. 4. Participants who have been toxin-naive for ≥1 year (i.e. onabotulinumtoxinA (BOTOX®), alternatives, or its derivatives)
  5. 5. Female subjects willing to minimize the risk of inducing pregnancy for the duration of clinical study
  6. 6. Subjects in good physical and mental health and not on any prescription psychiatric medications
  7. 7. Subjects willing to not undergo any other aesthetic or skin treatments for the duration of the study
  1. 1. Participants with history of facial (including periorbital) surgery within the last 12 months
  2. 2. Use of neuromodulators in the past ≤ 12 months
  3. 3. History or known alcohol and/or illicit drug abuse
  4. 4. Participants with psychiatric diagnosis
  5. 5. Body Mass Index (BMI) at Screening ≥ 30 kg/m2.
  6. 6. Participants with metabolic disorders (e.g., hypothyroidism and hyperparathyroidism)
  7. 7. Undiagnosed, unstable, or preexisting conditions that in the opinion of the investigators, would interfere with the course and conduct of the study. These include but are not limited to inflammatory disorders, diseases that affect muscles and/or nerves such as myasthenia gravis and Lambert-Eaton syndrome, high blood pressure, heart disease, and/or stroke that could result in a life-threatening response when treated with BOTOX® or placebo.
  8. 8. Participant has any laboratory abnormality (found on screening) that, in the opinion of the investigators, is clinically significant, has not resolved at baseline and could jeopardize or would compromise the participant's ability to participate in this study.
  9. 9. Prior use of isotretinoin
  10. 10. Active skin disease or infection at or near injection sites
  11. 11. Active use of tobacco or nicotine products in any form via any route (e.g. inhalation, ingestion, absorption)
  12. 12. Chronic marijuana or tetrahydrocannabinol exposure
  13. 13. If the investigators feel that the subject is not a good candidate for the study
  14. 14. Females of childbearing potential not using a reliable means of contraception
  15. 15. Female subjects must not be breastfeeding
  16. 16. Any known previous hypersensitivity reactions to BOTOX®
  17. 17. Current or recent (within therapeutic window) use of neuromuscular medications that may pose additional risk with treatment with BOTOX®, such as but not limited to amino-glycosides and anticholinergic drugs

Contacts and Locations

Study Contact

Principal Investigator
CONTACT
310-657-2203
drazizzadeh@gmail.com
Co-Principal Investigator
CONTACT
310-929-0142
clinicaltrial@facialplasticsbh.com

Principal Investigator

Babak Azizzadeh, MD, FACS
PRINCIPAL_INVESTIGATOR
Center for Advanced Facial Plastic Surgery
Marielle He, MD, MS
PRINCIPAL_INVESTIGATOR
Center for Advanced Facial Plastic Surgery

Study Locations (Sites)

Center for Advanced Facial Plastic Surgery
Beverly Hills, California, 90212-2913
United States

Collaborators and Investigators

Sponsor: Center for Advanced Facial Plastic Surgery

  • Babak Azizzadeh, MD, FACS, PRINCIPAL_INVESTIGATOR, Center for Advanced Facial Plastic Surgery
  • Marielle He, MD, MS, PRINCIPAL_INVESTIGATOR, Center for Advanced Facial Plastic Surgery

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-20
Study Completion Date2025-09

Study Record Updates

Study Start Date2025-01-20
Study Completion Date2025-09

Terms related to this study

Keywords Provided by Researchers

  • stress
  • BOTOX
  • PSS
  • Perceived stress scale
  • injection
  • reduction
  • BTA
  • facial rejuvenation
  • aesthetic procedure
  • psychological impact
  • clinical trial
  • facial expressions
  • stress relief
  • stress reduction
  • chemodenervation

Additional Relevant MeSH Terms

  • Stress (Psychology)
  • Stress
  • Healthy Adult Female Participants
  • Stress, Psychologic
  • Stress, Psychological Cumulative
  • Stress, Physiological
  • Stress Response
  • Stress Levels
  • Stress Perception